Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Formocresol is a dental medicament traditionally used as a devitalizing and fixative agent in pulpotomy procedures for primary teeth. It typically consists of a mixture of formaldehyde (the active fixative) and cresol (an antiseptic). The formaldehyde component works by cross-linking proteins and inactivating enzymes within the pulp tissue, effectively fixing the tissue and preventing further degradation or infection. Cresol serves to reduce the caustic nature of formaldehyde and provides additional antimicrobial properties. Despite its long history of use in pediatric dentistry, its safety has been questioned due to the potential systemic distribution and mutagenic properties of formaldehyde, leading to the investigation of alternative materials like mineral trioxide aggregate (MTA) or laser therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on formocresol.